期刊文献+

帕瑞昔布钠超前镇痛对全麻妇科手术术后镇痛的影响

原文传递
导出
摘要 目的观察妇科手术患者帕瑞昔布钠超前镇痛效果。方法择期全麻下妇科手术患者80例随机均分为四组:A组患者麻醉诱导前20min静注帕瑞昔布钠40mg,术毕行舒芬太尼静脉自控镇痛(PCIA);B组麻醉诱导前20min静注帕瑞昔布钠40mg,术后不用PCIA;C组麻醉诱导前20min静注生理盐水2ml,术后用PCIA;D组不用帕瑞昔布钠和PCIA作为空白对照。术后1、4、8、16和24h行视觉疼痛模拟评分(VAS)评分,记录术中舒芬太尼用量、术后镇痛药使用及不良反应。结果 A、B、C组术后VAS评分均明显低于D组(P<0.05)。A组4h和24hVAS评分明显低于B组(P<0.05)。B组术后1、4、8、16h的VAS评分明显高于C组(P<0.05)。术后需要追加哌替啶者的病例:D组7例;C组2例;B组3例;A组0例。不良反应包括恶心、呕吐、皮肤瘙痒和尿潴留,A、B、C三组均有少数病例发生(P>0.05);D组恶心、呕吐病例明显多于A组(10例vs.4例)(P<0.01)。结论帕瑞昔布钠超前镇痛对全麻妇科手术患者镇痛安全有效,增强术后阿片类药物镇痛效果,减少术后镇痛药物使用。
出处 《江苏医药》 CAS CSCD 北大核心 2011年第22期2702-2703,共2页 Jiangsu Medical Journal
  • 相关文献

参考文献6

  • 1Kissin I. Preemptive analgesia[J]. Anesthesiology, 2000, 93 (4) : 1138-1143.
  • 2Ardoin SP, Sundy JS. Update on nonsteriodal anti-inflamma- tory drugs[J]. Curr Opin Rheumatol, 2006,18(3) .. 221-226.
  • 3Moiniche S, Kehlet H, Dahl JB. Agualitative systematic review of preenptive analgesia for postoperative pain relief: the role of analgesia[J]. Anesthesiology, 2002,96 (4): 725-741.
  • 4Gottschalk A, Smith DS. New concepts in acute pain therapy preemptive analgesia [J]. Am Faro Physician, 2001, 63 ( 10 ) .. 1979-1984.
  • 5Kaye AD. Pharmacology of eyclooxygenase-2 inhihitors and preemptive analgesia in acute pain management[J]. Curr Opin Anaesthesiol, 2008,21 (4) : 439-445.
  • 6吴新民,岳云,张利萍,王俊科,艾登滨,于布为,薛张纲,黄文起.术后镇痛中帕瑞昔布钠对吗啡用量的节俭作用和安全性—前瞻性、多中心、随机、双盲、安慰剂对照、平行分组研究[J].中华麻醉学杂志,2007,27(1):7-10. 被引量:367

二级参考文献11

  • 1McArdle P. Intravenous analgesia. Crit Care Clin, 1999,15:89-104.
  • 2Bowdle TA. Adverse effects of opioid agonists and agonist-antagonists in anesthesia. Drug Saf, 1998,19:173-189.
  • 3Kehlet H, Dahl JB. The value of "multimodal" or "balanced analgesia"in postoperative pain treatment. Anesth Analg, 1993,77:1048-1056.
  • 4Power I, Barrett S. Analgesic agents for the postoperative period: nonopioids. Surg Clin North Am, 1999,79:275-295.
  • 5Tong D, Chung F. Postoperative pain control in ambulatory surgery. Surg Clin North Am, 1999,79:401-430.
  • 6Lipsky LP, Abramson SB, Crefford L, et al. The classification of cyclooxygenase inhibitors. J Rheumatol, 1998,25:2298-2303.
  • 7Penning TD, Talley JJ, Berteushaw SR, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenuse-2 inhihitors:identification of 4- [ 5- ( 4-methylphenyl ) -3- ( trifluoremethyl )- 1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem, 1997,40:1347-1365.
  • 8Tang J, Li S, White PF, et al. Effect of parecoxib, a novel intravenous cyclooxygenuse type-2 inhibitor, on the postoperative opioid requirement and quality of pain control. Anesthesiology, 2002,96: 1305-1309.
  • 9Malan TP Jr,Marsh G, Hakki SI, et al. Parecoxib sodium, a parenteral cyclooxygenuse 2 selective inhibitor, improves morphine analgesia and is opioid-sparing following total hip arthroplasty. Anesthesiology, 2003,98 :950-956.
  • 10Kranke P, Morin AM, Roewer N, et al. Patients' global evaluation of analgesia and safety of injected parecoxib for postoperative pain: a quantitative systematic review. Anesth Analg, 2004,99:797-806.

共引文献366

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部